Advancements in 3D Printing and Stem Cell Therapy offer Hope for Diabetes Treatment

Erin Bedford, head of bioprinting innovation at Aspect Biosystems, is leading a team that is developing a 3D printing process to create human pancreas cells for the treatment of Type 1 diabetes. The technology involves printing insulin-producing cells that can be injected into the body, potentially eliminating the need for organ transplants. Human trials are expected to begin soon, and the company has received a $75 million investment from Novo Nordisk. Aspect Biosystems is also exploring the possibility of printing other organs, such as livers.